GlycoMimetics Financial Statements From 2010 to 2025

GLYC Stock  USD 0.27  0.01  3.85%   
GlycoMimetics financial statements provide useful quarterly and yearly information to potential GlycoMimetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on GlycoMimetics financial statements helps investors assess GlycoMimetics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlycoMimetics' valuation are summarized below:
Gross Profit
10 K
Market Capitalization
17.5 M
Enterprise Value Revenue
555.3967
Revenue
10 K
Earnings Share
(0.59)
We have found one hundred twenty available fundamental trends for GlycoMimetics, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to confirm all of GlycoMimetics' regular performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 1, 2025, Market Cap is expected to decline to about 15.3 M. In addition to that, Enterprise Value is expected to decline to about 65.9 M

GlycoMimetics Total Revenue

10,000

Check GlycoMimetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlycoMimetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 217.6 K, Interest Expense of 56.3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 14.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.0029. GlycoMimetics financial statements analysis is a perfect complement when working with GlycoMimetics Valuation or Volatility modules.
  
Check out the analysis of GlycoMimetics Correlation against competitors.
For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

GlycoMimetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets11.6 B11.1 B1.5 B
Slightly volatile
Other Current LiabilitiesB5.7 B736.2 M
Slightly volatile
Total Current Liabilities6.1 B5.8 B748.4 M
Slightly volatile
Total Stockholder Equity5.6 B5.3 B738.9 M
Slightly volatile
Other Liabilities226 K237.9 K795.1 K
Slightly volatile
Current Deferred Revenue3.4 M3.6 M5.3 M
Slightly volatile
Accounts Payable312.8 K329.3 K1.2 M
Very volatile
Cash10.2 M10.7 M65.5 M
Pretty Stable
Non Currrent Assets Other1.1 M871.6 K890.7 K
Slightly volatile
Cash And Short Term Investments11.3 B10.7 B1.4 B
Slightly volatile
Common Stock Total Equity59.2 K56.4 K31.7 K
Slightly volatile
Common Stock Shares Outstanding35.6 M64.5 M30.6 M
Slightly volatile
Liabilities And Stockholders Equity11.6 B11.1 B1.5 B
Slightly volatile
Other Current Assets370.3 M371.3 M317.7 M
Pretty Stable
Other Stockholder Equity524.7 B499.7 B64.2 B
Slightly volatile
Total Liabilities6.1 B5.8 B749.4 M
Slightly volatile
Total Current Assets11.6 B11.1 B1.5 B
Slightly volatile
Common Stock37.7 K64.5 K32.4 K
Slightly volatile
Property Plant Equipment876.5 K1.1 M800.6 K
Slightly volatile
Net Tangible Assets46.9 M49.4 M75.1 M
Pretty Stable
Net Receivables149.1 K136.6 K108.1 K
Slightly volatile
Capital Surpluse304.1 M503.3 M284.8 M
Slightly volatile
Net Invested CapitalM5.3 M101.2 M
Slightly volatile
Net Working CapitalM5.3 M100.1 M
Slightly volatile
Capital Stock58.3 K64.5 K48.4 K
Slightly volatile
Short and Long Term Debt Total70.2 M66.8 M11.2 M
Slightly volatile
Capital Lease Obligations63.5 K66.8 K2.7 M
Slightly volatile
Short Term Debt70.3 M66.9 M9.3 M
Slightly volatile

GlycoMimetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization217.6 K176.3 K190.6 K
Slightly volatile
Other Operating Expenses42 B40 B5.2 B
Slightly volatile
Research Development15 B14.3 B1.8 B
Slightly volatile
Total Operating Expenses34.1 B32.5 B4.2 B
Slightly volatile
Selling General Administrative19.2 B18.2 B2.3 B
Slightly volatile
Non Operating Income Net Other786.3 K748.9 K394 K
Slightly volatile
Interest Income1.3 M935.3 K829.8 K
Slightly volatile
Reconciled Depreciation33.4 K35.2 K228.1 K
Slightly volatile
Net Interest Income1.3 M935.3 K2.4 M
Slightly volatile
Selling And Marketing Expenses510573625
Slightly volatile

GlycoMimetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.9 B4.7 B604.6 M
Slightly volatile
Begin Period Cash Flow43.9 B41.8 B5.4 B
Slightly volatile
Depreciation36.9 M35.2 M4.7 M
Slightly volatile
Capital Expenditures9.5 K10 K170.1 K
Slightly volatile
End Period Cash Flow11.3 B10.7 B1.4 B
Slightly volatile
Sale Purchase Of Stock15.5 M16.3 M41.2 M
Slightly volatile
Change To Netincome4.9 M5.4 M3.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.1 K13.5 K3.3 K
Slightly volatile
PTB Ratio0.00290.0032.0901
Pretty Stable
Days Sales Outstanding6.1 K5.8 K1.5 K
Slightly volatile
Book Value Per Share86.5382.409913.8116
Slightly volatile
Average Payables1.1 M538.8 K1.1 M
Pretty Stable
Stock Based Compensation To Revenue33632077.3539
Slightly volatile
Capex To Depreciation3.0E-43.0E-41.0949
Slightly volatile
PB Ratio0.00290.0032.0901
Pretty Stable
Payables Turnover1.010.960.4116
Slightly volatile
Sales General And Administrative To Revenue1.8 K1.7 K389
Slightly volatile
Research And Ddevelopement To Revenue1.9 K1.8 K466
Slightly volatile
Capex To Revenue3.41.932.995
Very volatile
Cash Per Share17516626.9408
Slightly volatile
Days Payables Outstanding3753952.3 K
Slightly volatile
Current Ratio1.821.91967.4488
Pretty Stable
Tangible Book Value Per Share86.5382.409913.8116
Slightly volatile
Receivables Turnover0.06210.06541.5 K
Very volatile
Graham Number3.083.2411.6668
Slightly volatile
Shareholders Equity Per Share86.5382.409913.8116
Slightly volatile
Debt To Equity0.02280.01260.0224
Slightly volatile
Capex Per Share1.0E-42.0E-40.0448
Slightly volatile
Average Receivables62.1 K65.4 K104.6 K
Pretty Stable
Revenue Per Share2.0E-42.0E-41.5785
Slightly volatile
Interest Debt Per Share1.091.03670.4096
Very volatile
Debt To Assets0.00570.0060.0189
Slightly volatile
Price Book Value Ratio0.00290.0032.0901
Pretty Stable
Days Of Payables Outstanding3753952.3 K
Slightly volatile
Ebt Per Ebit1.080.93950.9962
Pretty Stable
Company Equity Multiplier1.582.08741.5739
Slightly volatile
Total Debt To Capitalization0.02220.01240.0219
Slightly volatile
Debt Equity Ratio0.02280.01260.0224
Slightly volatile
Quick Ratio1.821.919641.156
Pretty Stable
Net Income Per E B T0.981.81.1317
Slightly volatile
Cash Ratio0.00180.00197.0084
Very volatile
Days Of Sales Outstanding6.1 K5.8 K1.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00031.0153
Pretty Stable
Price To Book Ratio0.00290.0032.0901
Pretty Stable
Fixed Asset Turnover0.01420.01510.1634
Slightly volatile
Debt Ratio0.00570.0060.0189
Slightly volatile
Price Sales Ratio14.1 K13.5 K3.3 K
Slightly volatile
Asset Turnover2.0E-43.0E-40.1765
Slightly volatile
Price Fair Value0.00290.0032.0901
Pretty Stable

GlycoMimetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.3 M16.1 M132 M
Pretty Stable

GlycoMimetics Fundamental Market Drivers

Cash And Short Term Investments10.7 B

GlycoMimetics Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About GlycoMimetics Financial Statements

GlycoMimetics stakeholders use historical fundamental indicators, such as GlycoMimetics' revenue or net income, to determine how well the company is positioned to perform in the future. Although GlycoMimetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in GlycoMimetics' assets and liabilities are reflected in the revenues and expenses on GlycoMimetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in GlycoMimetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.6 M3.4 M
Cost Of Revenue138 K131.1 K
Stock Based Compensation To Revenue 320.44  336.46 
Sales General And Administrative To Revenue1.7 K1.8 K
Research And Ddevelopement To Revenue1.8 K1.9 K
Capex To Revenue 1.93  3.40 
Ebit Per Revenue-4.5 K-4.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:
Check out the analysis of GlycoMimetics Correlation against competitors.
For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.59)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.72)
Return On Equity
(1.73)
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.